Loading... (0%)

News + Events

news

3-V Biosciences Announces Closing of $28.5M Financing Round

30 December 2014

Menlo Park, California, December 30, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today the closing of its Series D round of financing co-led by NEA, Kleiner Perkins and Rock Springs Capital Management and includes other new investors such as Ally Bridge Group….

3-V Biosciences to Present at the 25th Annual Oppenheimer Healthcare Conference

04 December 2014

Menlo Park, California, December 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, announced today that Chief Executive Officer, Merdad Parsey, M.D., Ph.D., will present at the 25th Annual Oppenheimer Healthcare Conference on Thursday, December 11, 2014 at 9:10 AM EST at the Crowne…

3-V Biosciences Announces Presentation of First Human Clinical Data for Lead Oral FASN Inhibitor Candidate at EORTC-NCI-AACR 2014

19 November 2014

Barcelona, Spain, November 19, 2014. 3-V Biosciences, Inc., (3-V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, today presented the first human clinical data for its first-in-class lead oncology candidate, TVB-2640, at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics currently taking place in Barcelona, Spain….

3-V Biosciences to Present Clinical and Preclinical Data for FASN Inhibitors at EORTC-NCI-AACR 2014

02 October 2014

Menlo Park, California, October 2, 2014. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious diseases, will present clinical data for its lead therapeutic compound, TVB-2640, in a late-breaking oral session at the 26th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics on November 18 – 21,…

3-V Biosciences Commences Patient Dosing in Phase 1 Clinical Study of FASN Inhibitor TVB- 2640 in Patients with Advanced Solid Tumors First

04 December 2013

FASN Anti-Tumor Candidate in Clinical Development Menlo Park, California, December 4, 2013. 3-V Biosciences, Inc., a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the recent initiation of a Phase 1 clinical study of TVB-2640 in patients with advanced solid tumors. TVB-2640 is an oral, proprietary fatty…

3-V Biosciences Names Dr. William McCulloch Chief Medical Officer

21 November 2013

Menlo Park, California, November 21, 2013. 3-V Biosciences, Inc. (3‐V), a clinical-stage biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced that William McCulloch, MB, ChB, FRCP, FFPM has joined the company as Chief Medical Officer. Dr. McCulloch brings nearly three decades of senior research and development experience to…

3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

23 October 2013

3-V’s Small Molecule Tumor Metabolism Inhibitor Demonstrates Single-Agent Activity; Halts Tumor Growth and Induces Tumor Regression Menlo Park, California, October 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pathways resulting in death of tumor cells or virally-infected cells, today presented positive data from preclinical studies of the company’s novel…

3-V Biosciences Completes $20 Million Series C Financing

21 June 2013

Menlo Park, California, June 21, 2013. 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key pathways in oncology and infectious disease, today announced the completion of a Series C financing round, raising $20 million. Proceeds from the financing will be used to advance 3-V’s lead oncology candidate into a Phase 1 clinical trial…

3­‐V Biosciences presented two publications at AASLD

03 December 2012

3­‐V Biosciences presented two publications at the 63rd Annual Meeting of the American Association for the Study of Liver Diseases (The Liver Meeting®) held November 9‐13 in Boston, Massachusetts. BACKGROUND: Optimized new therapies for HCV are needed that have pan genotypic activity and a high barrier to viral resistance. To meet these challenges, 3-V Biosciences…

3–V Biosciences Presents Positive Preclinical Data on HCV Product Candidates Targeting FASN at the American Association for the Study of Liver Disease Annual Meeting 2012

12 November 2012

Small Molecule FASN Inhibitors Demonstrate Antiviral Activity Menlo Park, California, November 10, 2012. 3–V Biosciences, Inc., announced today that preclinical data for its novel fatty acid synthase (FASN) inhibitors for the treatment of chronic hepatitis C virus (HCV) infection will be presented at the 63rd Annual Meeting of the American Association for the Study of…